On July 30, 2019, the FDA approved darolutamide (Nubeqa; Bayer) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.